Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.68 |
| ▸ | PDE7A | Q13946 | 10/20 | 0.43 |
| ▸ | PDE4A | P27815 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237399 | 0.85 | CHRM1 (0.72) | CHRM1PDE7APDE4ALMNA | |
| SCHEMBL2877481 | 0.85 | CHRM1 (0.86) | CHRM1HTTLMNA | |
| SCHEMBL3230348 | 0.85 | CHRM1 (0.72) | CHRM1PDE7APDE4ALMNA | |
| SCHEMBL3234568 | 0.83 | CHRM1 (0.51) | CHRM1ALDH1A1HTTLMNA | |
| SCHEMBL2883197 | 0.82 | CHRM1 (0.80) | CHRM1LMNA | |
| SCHEMBL2883219 | 0.81 | CHRM1 (0.76) | CHRM1ALDH1A1LMNA | |
| SCHEMBL3230296 | 0.81 | CHRM1 (0.66) | CHRM1PDE7APDE4ALMNA | |
| SCHEMBL3236683 | 0.81 | CHRM1 (0.66) | CHRM1PDE7APDE4ALMNA | |
| SCHEMBL2486076 | 0.81 | CHRM1 (1.00) | CHRM1LMNA | |
| SCHEMBL3238090 | 0.81 | CHRM1 (0.46) | CHRM1PDE7APDE4AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | claimed |
| US-20100317692-A1 | Quinolone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | claimed |
| EP-1963271-B1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2010-07-28 | — | — | EP | claimed |
| WO-2007100366-A2 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | claimed |
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-1963271-B1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1963271-B1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2007100366-A2 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007067489-A1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317692-A1 | Quinolone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, MTNR1A | CHRM1 1/4885PDE7A 242/4885PDE4A 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.